BioCentury | Aug 11, 2014
Strategy

Profusion of exclusions

Express Scripts Holding Co. 's 2015 formulary exclusions offer hope that companies can renegotiate once-excluded drugs back into coverage. But the pharmacy benefits manager appears to be expanding the number of drugs and drug classes...
BC Week In Review | Oct 31, 2011
Clinical News

Euflexxa sodium hyaluronate regulatory update

FDA approved an updated label for Euflexxa sodium hyaluronate from Ferring to treat pain from osteoarthritis (OA) of the knee. The new label includes efficacy data from the 26-week, double-blind FLEXX trial and 52-week safety...
BC Week In Review | May 25, 2009
Clinical News

Euflexxa Sodium hyaluronate: Post-marketing study data

Data from a double-blind trial in 586 patients showed that Euflexxa significantly reduced pain scores from baseline compared with saline at week 26 (25.7 vs. 18.5 points, p=0.002). A significantly higher proportion of Euflexxa patients...
BC Week In Review | Nov 21, 2005
Company News

Ferring sales and marketing update

Ferring launched its Euflexxa purified hyaluronan to treat pain caused by osteoarthritis (OA) of the knee. Ferring gained the product in July when it bought the biologics manufacturing business of Savient Pharmaceuticals Inc. (SVNTE, East...
BC Week In Review | Mar 28, 2005
Company News

Savient, Ferring Holding SA deal

SVNT agreed to sell its global biologics manufacturing business to Ferring's Ferring B.V. and Ferring International Centre SA subsidiaries for $80 million in cash. SVNT will receive $55 million at deal close, $15 million at...
BC Extra | Mar 24, 2005
Company News

Savient sells manufacturing business

SVNT agreed to sell its global biologics manufacturing business to Ferring (Lausanne, Switzerland) for $80 million in cash. SVNT will receive $55 million at deal close, $15 million at the first anniversary of the closing,...
BC Week In Review | Dec 20, 2004
Clinical News

Nuflexxa regulatory update

FDA approved a PMA for Nuflexxa to treat pain in patients with osteoarthritis (OA) who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. The non-avian derived hyaluronic acid is also approved...
Items per page:
1 - 7 of 7